JP2024528039A5 - - Google Patents
Info
- Publication number
- JP2024528039A5 JP2024528039A5 JP2024505230A JP2024505230A JP2024528039A5 JP 2024528039 A5 JP2024528039 A5 JP 2024528039A5 JP 2024505230 A JP2024505230 A JP 2024505230A JP 2024505230 A JP2024505230 A JP 2024505230A JP 2024528039 A5 JP2024528039 A5 JP 2024528039A5
- Authority
- JP
- Japan
- Prior art keywords
- raf
- inhibitor
- administered
- mek
- combination according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163203555P | 2021-07-27 | 2021-07-27 | |
| US63/203,555 | 2021-07-27 | ||
| PCT/US2022/038434 WO2023009572A1 (en) | 2021-07-27 | 2022-07-27 | Combination therapy for treating abnormal cell growth |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024528039A JP2024528039A (ja) | 2024-07-26 |
| JP2024528039A5 true JP2024528039A5 (enExample) | 2025-08-04 |
Family
ID=85087234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024505230A Pending JP2024528039A (ja) | 2021-07-27 | 2022-07-27 | 異常な細胞成長を処置するための組み合わせ治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250049792A1 (enExample) |
| EP (1) | EP4376828A4 (enExample) |
| JP (1) | JP2024528039A (enExample) |
| KR (1) | KR20240041978A (enExample) |
| CN (1) | CN118103040A (enExample) |
| AU (1) | AU2022318885A1 (enExample) |
| CA (1) | CA3227498A1 (enExample) |
| IL (1) | IL310477A (enExample) |
| MX (1) | MX2024001248A (enExample) |
| WO (1) | WO2023009572A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021206684B2 (en) | 2020-01-10 | 2024-01-18 | Immuneering Corporation | MEK inhibitors and therapeutic uses thereof |
| JP2025510572A (ja) | 2022-03-08 | 2025-04-15 | レボリューション メディシンズ インコーポレイテッド | 免疫不応性肺癌を治療するための方法 |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| CN119947725A (zh) * | 2022-09-30 | 2025-05-06 | 应世生物科技(南京)有限公司 | Fak抑制剂及诱导免疫原性细胞死亡的物质的药物组合及用途 |
| WO2024173761A1 (en) * | 2023-02-17 | 2024-08-22 | Ikena Oncology, Inc. | Combinations comprising mek inhibitors for use in the treatment of cancer |
| CR20250420A (es) | 2023-04-07 | 2025-11-20 | Revolution Medicines Inc | Inhibidores macrocíclicos de ras |
| AR132338A1 (es) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | Inhibidores de ras |
| CN121464140A (zh) | 2023-04-14 | 2026-02-03 | 锐新医药公司 | Ras抑制剂的结晶形式、含有其的组合物及其使用方法 |
| CN121100123A (zh) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Ras抑制剂的结晶形式 |
| TW202508595A (zh) * | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016115376A1 (en) * | 2015-01-14 | 2016-07-21 | The Regents Of The University Of California | Detection and treatment of double drug resistant melanomas |
| JP2022547358A (ja) * | 2019-09-13 | 2022-11-14 | ジ インスティテュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル | 治療組成物、組み合わせ、及び使用方法 |
| AU2021206684B2 (en) * | 2020-01-10 | 2024-01-18 | Immuneering Corporation | MEK inhibitors and therapeutic uses thereof |
-
2022
- 2022-07-27 US US18/292,086 patent/US20250049792A1/en active Pending
- 2022-07-27 IL IL310477A patent/IL310477A/en unknown
- 2022-07-27 AU AU2022318885A patent/AU2022318885A1/en active Pending
- 2022-07-27 KR KR1020247006593A patent/KR20240041978A/ko active Pending
- 2022-07-27 WO PCT/US2022/038434 patent/WO2023009572A1/en not_active Ceased
- 2022-07-27 CA CA3227498A patent/CA3227498A1/en active Pending
- 2022-07-27 EP EP22850215.9A patent/EP4376828A4/en active Pending
- 2022-07-27 CN CN202280063475.8A patent/CN118103040A/zh active Pending
- 2022-07-27 MX MX2024001248A patent/MX2024001248A/es unknown
- 2022-07-27 JP JP2024505230A patent/JP2024528039A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024528039A5 (enExample) | ||
| JP2023534009A5 (enExample) | ||
| JP2024540015A5 (enExample) | ||
| Liang et al. | Adjuvant chemotherapy of completely resected early stage non-small cell lung cancer (NSCLC) | |
| JP2020514311A5 (enExample) | ||
| CN115624550B (zh) | 一种用于治疗胃癌的喹啉衍生物 | |
| JP2023523323A5 (enExample) | ||
| CN105120663B (zh) | 用于利用羧胺三唑乳清酸盐治疗对先前化学治疗药物和靶向药物具有获得性耐药性的癌症的方法和组合物 | |
| JP2021524835A5 (enExample) | ||
| JP2017526662A5 (enExample) | ||
| JP2024519845A5 (enExample) | ||
| Jiang et al. | Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer: an observational pilot study. | |
| WO2017118401A1 (zh) | 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒 | |
| Zhang et al. | FNC, a novel nucleoside analogue, blocks invasion of aggressive non-Hodgkin lymphoma cell lines via inhibition of the Wnt/β-catenin signaling pathway | |
| JP2024524461A5 (enExample) | ||
| Ilson | Immunotherapy in esophagogastric cancer | |
| JP2024528705A5 (enExample) | ||
| JP2022501332A5 (enExample) | ||
| JP2021511344A5 (enExample) | ||
| JP2023550740A5 (enExample) | ||
| WO2019016928A1 (ja) | がん細胞の代謝の特異性に基づく新規抗悪性腫瘍剤 | |
| TW202120085A (zh) | 抗ccr4抗體抵抗性之癌症的治療劑 | |
| Bancewicz et al. | Adjuvant chemotherapy and immunotherapy for colorectal cancer: preliminary communication | |
| CN112870365A (zh) | Ezh2抑制剂和/或parp抑制剂与化疗药物联合在制备治疗肿瘤药物中的用途 | |
| JP2023542523A5 (enExample) |